Videos

Dedee F. Murrell, MD, details the EASE trial findings presented at AAD 2022, and what the benefit of the novel topical gel may mean for patients with EB.

The ALLEGRO study detailed the efficacy and safety of ritlecitinib in adult and adolescent patients with the alopecia areata.

The agent may become approved this year for children aged 6 months to 5 years old. Amy S. Paller, MD, discusses what impact it could bring.

Dr. Raj Chovatiya provides updates from AAD on some pending and potential FDA approvals for several dermatology therapies.

With no approved therapies currently available, Dr. Brett King feels that the JAK inhibitor baricitinib could provide patients with a long sought after solution to hair loss.

New AAD 2022 data show the novel gene therapy from Krystal Biotech provided wound healing by 3 months in patients with dystrophic epidermolysis bullosa.

Dr. Gil Yosipovitch suspects that dupilumab will be approved for use in patients with prurigo nodularis based on new data from the LIBERTY-RN PRIME2 trial.

The Feinberg School of Medicine expert discusses the impact of dupilumab and other biologics on severely affected children and adolescnets.

An expert delves into the increased risk of conditions including psoriasis flares, lupus, and scleroderma following COVID-19.

Data from the 5-year extension trial ECZTEND indicated that the overall safety profile of tralokinumab was consistent with the previous ECZTRA trials.

Dr. David Rosmarin follows up his AAD presentation with an interview on ruxolitinib cream for facial and body repigmentation in patients with vitiligo.

John E. Harris, MD, PhD, discusses the delayed decision date for the topical JAK inhibitor, and what more needs to be researched on the drug.

John E. Harris, MD, PhD, explains how JAK inhibitors and biologic therapy may advance the field from "Iron Age" era treatment strategy.

The increased risk of cancer development in patients with atopic dermatitis has been suggested due to chronic inflammation or immunologic defects inherent to the disease and various treatments.

Dr. Daphne Chan spoke of representation in psoriasis trials, how psoriasis affects different skin types, and how the VISIBLE study can influence dermatology research at large.

The advent of biologics has transformed care for patients with inflammatory bowel disease.

Subhdeep Virk, MBBS, chaired the recent State of the Science event on treatment-resistant depression.

After more promising long-term data, Apellis announced plans to seek regulatory approval. An investigator explains what value it could bring to patients.

Approximately 60% of patients with ulcerative colitis treated with guselkumab achieved clinical remission.

New data on FT218 will be presented at the World Sleep 2022 conference in Rome.

Dr. Avidan speaks of the increased prevalence of insomnia and sleep-wake patterns and promising new therapies for sleep disorders including narcolepsy.

Dr. Garcia-Molina speaks to how smart bed technology can unobtrusively collect data to predict and track the development of symptoms associated with respiratory illnesses.

The University of Colorado expert joins for a 5-part interview on making sense of the boom of new agents and care strategies.

The Yale Associate Chief of Cardiovascular Medicine discusses improved use of available drug classes, as well as the potential approval for omecamtiv mecarbil.

The Johns Hopkins expert details recent advances in remote cardiovascular care and research, and explains how the field will continue to evolve.

By blocking certain neurogenic changes that occur in the lungs at childhood, patients may avoid asthma and allergic responses into adulthood.

Currently, antibiotics comprise roughly 80% of prescribed pregnancy medications, and recent epidemiological studies have indicated a link between antibiotic use and dysbiosis.

Dr. Mathias noted that investigators are continuing to determine if age plays a role in peanut allergy risk and sensitization.